Tositumomab

Jump to: navigation, search
Tositumomab
Monoclonal antibody
TypeWhole antibody
SourceTemplate:Infobox drug/mab source
TargetCD20
Clinical data
Trade namesBexxar
AHFS/Drugs.comMonograph
MedlinePlusa609013
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC6416H9874N1688O1987S44
Molar mass143859.7 g/mol
 ☒N☑Y (what is this?)  (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tositumomab was a drug that was approved for the treatment of relapsed or chemotherapy/rituxan-refractory Non-Hodgkin lymphoma in 2003.[1] It was sold in the U.S. and Canada under the trade name Bexxar. Sale of the drug was discontinued and marketing approval was withdrawn in February 2014 due to the decline in usage (fewer than 75 patients in 2012) and the existence of other similar drugs.[2][3]

This drug combination was developed by Corixa which was purchased by GlaxoSmithKline) in 2005.[4]

References

  1. New York Times. July 1, 2003 Company News: Corixa and Glaxo's Cancer Drug Wins FDA Approval
  2. "Why Good Drugs Sometimes Fail: The Bexxar Story".
  3. Notice by the Food and Drug Administration on October 23, 2013. GlaxoSmithKline LLC; Withdrawal of Approval of the Indication for Treatment of Patients With Relapsed or Refractory, Low Grade, Follicular, or Transformed CD20 Positive Non-Hodgkin's Lymphoma Who Have Not Received Prior Rituximab; BEXXAR
  4. Carla Mozee for MarketWatch. April 29, 2005 Glaxo to acquire Corixa for $300 million

Linked-in.jpg